Lipid nanocapsules: A new platform for nanomedicine

Huynh, Ngoc Trinh; Passirani, Catherine; Saulnier, Patrick; Benoit, Jean‐Pierre

doi:10.1016/j.ijpharm.2009.04.026

Cited by 480 publications

(287 citation statements)

References 72 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…In all LPS-treated cohorts, the neutrophilic response was fully resolved by t = 72 h post-administration of LPS (data not shown). M A N U S C R I P T ACCEPTED MANUSCRIPT 8 Lipid nanocapsule treatment using an o.a. procedure did not induce acute inflammation in healthy lungs (Fig.…”

Section: Lung Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration

Patel

Woods

Riffo‐Vasquez

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

Lipid nanocapsules (LNCs) are semi-rigid spherical capsules with a triglyceride core that present a promising formulation option for the pulmonary delivery of drugs with poor aqueous solubility. Whilst the biodistribution of LNCs of different size has been studied following intravenous administration, the fate of LNCs following pulmonary delivery has not been reported. We investigated quantitatively whether lung inflammation affects the clearance of 50 nm lipid nanocapsules, or is exacerbated by their pulmonary administration. Studies were conducted in mice with lipopolysaccharide-induced lung inflammation compared to healthy controls. Particle deposition and nanocapsule clearance kinetics were measured by single photon emission computed tomography/computed tomography (SPECT/CT) imaging over 48 h. A significantly lower lung dose of 111 In-LNC50 was achieved in the lipopolysaccharide (LPS)-treated animals compared with healthy controls (p < 0.001). When normalised to the delivered lung dose, the clearance kinetics of 111 In-LNC50 from the lungs fit a first order model with an elimination half-life of 10.5 ± 0.9 h (R 2 = 0.995) and 10.6 ± 0.3 h (R 2 = 1.000) for healthy and inflamed lungs respectively (n = 3). In contrast, 111 In-diethylene triamine pentaacetic acid (DTPA), a small hydrophilic molecule, was cleared rapidly from the lungs with the majority of the dose absorbed within 20 min of administration. Biodistribution to lungs, stomach-intestine, liver, trachea-throat and blood at the end of the imaging period was unaltered by lung inflammation. This study demonstrated that lung clearance and whole body distribution of lipid nanocapsules were unaffected by the presence of acute lung inflammation.

show abstract

Section: Lung Inflammationmentioning

confidence: 99%

“…the anti-cancer agents, paclitaxel and tretinoin) [7][8][9][10]. The core is surrounded by a semi-rigid shell typically consisting of phosphotidylcholines and surfactants [11].…”

Section: Introductionmentioning

confidence: 99%

Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration

Patel

Woods

Riffo‐Vasquez

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…In past decade, drug delivery made with nanoparticles or nanovesicles has brought great commercial benefits in the industry, with 24 products exceeding 5 billion US dollar sales (Huynh et al 2009;Jatariu et al 2009;Kateb et al 2010;Provenzale and Silva 2009). …”

Section: Nanoparticlesmentioning

confidence: 99%

“…Various nanoparticles since then were designed and developed, including poly(ethylene oxide)-poly(L-lactic acid)/poly(b-benzyl-L-aspartate), poly(lactideco-glycolide)-[(propylene oxide)-poly(ethylene oxide)], polyphosphazene derivatives, poly(ethylene glycol)-coated nanospheres, azidothymidin (AZT)/dideoxycytidine (ddc) nanoparticles, poly (isobutylcynoacrylate) nanocapsules, poly(g-benzyl-L-glutamate)/poly(ethylene oxide), chitosan-poly(ethylene oxide) nanoparticles, methotrexate-o-carboxymethylate chitosan, solid lipid nanoparticles (SLNs), and so on (Blasi et al 2009;Caruso et al 2010;Chekhonin et al 2009;Fonseca et al 2009;Gilmore et al 2008;Graf et al 2009;Huynh et al 2009;Jatariu et al 2009;Kaur et al 2008;Khalil and Mainardes 2009;Ljubimova et al 2008;Mistry et al 2009b;Modi et al 2010;Namdeo et al 2008;Shilpi et al 2007;Tosi et al 2008;Wong et al 2010). Further to these polymer nanoparticles, there are metal-based, lipid-based, and biological nanoparticles.…”

Section: Variety Of Nanoparticlesmentioning

confidence: 99%

“…Secondly, the biodegration of nanoparticles would vary due to the different natures of the materials, the diverse biodegrading activity of enzymes among tissues, and the co-applied adjuvants. Thirdly, it would be ideal to design multi-layer nanoparticles with adjustable degrading curve, with a controlled drug release (Denora et al 2009;Huynh et al 2009;Jatariu et al 2009). Adjuvants could be further combined to regulate the release of specific drugs from the nanoparticle when needed.…”

Section: Drug Release From Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Nanomaterials in controlled drug release

Cai

2011

Cytotechnology

View full text Add to dashboard Cite

In past years with the advances of chemistry and material sciences, the development of nanotechnology brought generations of nanomaterials with specific biomedical properties. These include the nanoparticle-based drug delivery, nanosized drugs, and nanomaterials for tissue engineering. The present article focuses on the use of nanomaterials in controlled drug release. The applications of nanomaterials with nanoenabled drug release characteristics brought many benefits when compared to the traditional (bulk) materials. We discuss the current advances and propose some future directions for the technology development.

show abstract

Hierarchically Organized Systems Based on Liquid Crystalline Phases

Kulkarni

Glatter

2012

Self‐Assembled Supramolecular Architectures

View full text Add to dashboard Cite

Lipid nanocapsules: A new platform for nanomedicine

Cited by 480 publications

References 72 publications

Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration

Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration

Nanomaterials in controlled drug release

Hierarchically Organized Systems Based on Liquid Crystalline Phases

Contact Info

Product

Resources

About